What is Bio-Sourcing?
Bio-Sourcing operates as a specialized biotechnology enterprise focused on the sustainable production of complex biotherapeutics. The company has pioneered a unique platform that utilizes goat milk as a biological medium for protein expression, a method that offers significant cost and efficiency advantages over conventional bioreactor systems. By integrating sophisticated genome editing techniques, Bio-Sourcing is able to produce high-quality monoclonal antibodies, which are critical components in modern oncology and immunology treatments. This innovative approach addresses the growing global demand for affordable, high-yield biopharmaceutical manufacturing, effectively bridging the gap between laboratory-scale research and large-scale industrial production. The company's market position is defined by its ability to combine agricultural biotechnology with high-end pharmaceutical standards, creating a robust and profitable pipeline for therapeutic development.
How much funding has Bio-Sourcing raised?
Bio-Sourcing has raised a total of $13.6M across 2 funding rounds:
Grant
$2.7M
Private Equity
$10.9M
Grant (2024): $2.7M with participation from The European Innovation Council
Private Equity (2024): $10.9M led by The European Innovation Council
Key Investors in Bio-Sourcing
The European Innovation Council
The European Innovation Council is a prominent funding body that supports high-impact research and innovation, focusing on scaling breakthrough technologies within the European market.
What's next for Bio-Sourcing?
With this recent infusion of capital, Bio-Sourcing is poised to accelerate its clinical development programs and expand its manufacturing infrastructure. The strategic focus will likely shift toward scaling its genome-edited livestock operations to meet the rigorous requirements of international regulatory bodies. As the company transitions from a development-stage entity to a commercial-ready enterprise, the primary objective will be to validate its platform through successful clinical trials and establish long-term partnerships with major pharmaceutical firms. The investment provides the necessary runway to optimize its proprietary production cycles, ensuring that the company remains a competitive force in the rapidly evolving biotherapeutics landscape. Future growth will be contingent upon the successful scaling of its unique production model and the continued validation of its monoclonal antibody efficacy in human trials.
See full Bio-Sourcing company page
